How targeted cancer drugs affect thinking and memory
Official title: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11137786 · Data updated 2026-11-12
We will follow people with CML or CLL who are starting tyrosine kinase inhibitor treatment to find out if these targeted drugs change thinking, memory, or attention.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $664,612 |
| NIH project number | 5R01CA287666-02 |
| Project ID | NIH-11137786 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL) who are about to start treatment with a tyrosine kinase inhibitor are ideal candidates.
✕Less likely to help
People not starting TKIs, those with other cancer types, or whose cognitive issues stem from unrelated causes may not receive direct benefit from this work.
What this research studies
If you join, researchers will enroll people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL) before they start a tyrosine kinase inhibitor and follow them over time. You will complete standardized neuropsychological tests (CANTAB) and brief real-time surveys on a smartphone (ecological momentary assessment) to track thinking, memory, and attention. The team will also collect medical and biological information to look for risk factors and possible biological mechanisms. The study will capture both how patients feel about their cognition and how they perform on objective tests.
Why it matters
Potential benefit: If successful, the work could help doctors recognize, prevent, or manage thinking and memory problems linked to targeted cancer drugs.
How similar studies have gone: Prior smaller studies and validated tools like CANTAB and EMA support this approach, but large prospective studies of TKIs and cognition are novel.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Gonzalez, Brian D — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Gonzalez, Brian D
Related research
Other NIH-funded projects on the same topics.
-
Impact of Targeted Cancer Therapy on Thinking and Memory
This research looks at how targeted cancer drugs (TKIs) affect thinking and memory in patients starting treatment for certain blood cancers.
-
Effects of targeted cancer therapy on cognitive function in survivors
This study is looking at how certain cancer treatments called tyrosine kinase inhibitors (TKIs) might affect thinking and memory in people who have survived chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL), so we can better understand the challenges they face while on these therapies.
-
Improving Neurological Health with Brain Training for Mild Cognitive Impairment (INHANCE-MCI)
A computer-based brain training program is being tested to help people with mild cognitive impairment maintain thinking skills and daily functioning.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Global picture of dementia risk and memory loss across the world
A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.